We appreciate the holistic approach and are so happy we found Five Journeys
It was then followed by liraglutide 1.8 mg (Victoza, Novo Nordisk) in 2009, dulaglutide 1.5 mg (Trulicity, Eli Lilly) in 2014, and liraglutide 3.0 mg (Saxenda, Novo Nordisk) in 2014
Personalized Dosing Medication dosage and timing are customized to minimize discomfort and support long-term success
Accordingly, we encourage the adoption of GLP-1RA plus SGLT2i combination therapy in patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors for ASCVD (i.e., age 55 years, overweight/obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria)